Recordati acquires French OTC firm Tonipharm

22 December 2018

In what was a busy week for the Italian drugmaker, Recordati (RECI: MI) reached an agreement for the acquisition of 100% of the share capital of Tonipharm, a French company based in Boulogne-Billancourt near Paris, active mainly in the self-medication market with over-the-counter (OTC) products.

The company is expected to realize sales of around 26.5 million euros ($30.3 million) in 2018. The closing of the transaction, financial terms of which are not disclosed, is planned to take place at year-end, said Recordati, whose shares gained 2.19% to 30.30 euros following the announcement on Friday.

Tonipharm was established in 1991 and promotes a wide portfolio of self-medication products together with some prescription drugs. The company’s sales are generated mainly by the line of products sold under the umbrella brand Ginkor, OTC treatments based on ginko biloba which are very well known on the French market. The company also promotes Alodont, a line of products used for oral hygiene.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK